ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: fracture

Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women

Reuters Staff  |  

NEW YORK (Reuters Health)—Although histomorphometry of iliac bone gives precise results, bone turnover markers provide a better reflection of the overall skeleton in untreated postmenopausal osteoporotic women, according to French researchers. Bone histomorphometry allows study of bone remodeling at the basic structural unit level, Dr. Pascale Chavassieux and colleagues at the University of Lyon note…

BMI Feasible As Pre-Screening Tool for Osteoporosis in Women

Larry Hand  |  

NEW YORK (Reuters Health)—A body mass index (BMI) of less than 28 alone may be a tool to prescreen younger postmenopausal women for osteoporosis, according to a new study. “For young postmenopausal white women aged 50–64, current prescreening modalities identifying candidates for DXA (dual-energy X-ray absorptiometry) scan … are not performing better than BMI alone,”…

Knee Replacement Surgery Works, but So Can Nonsurgical Techniques

Gene Emery  |  

(Reuters Health)—Total knee replacement can usually relieve pain and improve function, but a nonsurgical regimen can also be effective in some people without posing the complication risks of surgery, according to a new study. The study found that while 85% of patients who underwent surgery showed clinically-significant improvement after one year, so did 67% assigned…

FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

Michele B. Kaufman, PharmD, CGP, RPh  |  

The U.S. Food and Drug Administration (FDA) has toughened the existing warnings for nonsteroidal anti-inflammatory drugs (NSAIDs) due to their stroke and myocardial infarction (MI) risk increase.1 Due to a continual review of these products, FDA is requiring label updates for all prescription NSAIDs. Over-the-counter (OTC) NSAIDs already list the increased risk of MI and…

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Bone Loss Common in Suspected Spondyloarthritis

David Douglas  |  

NEW YORK (Reuters Health)—More than 40% of patients with early inflammatory back pain suggestive of axial spondyloarthritis (SpA) show bone loss over the course of two years, according to French researchers. SpA is known to be associated with bone loss at the spine and the hip and an increased risk of vertebral fractures. To investigate…

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

  |  

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Vitamin D in Rheumatology: Cause and Effect Unclear

  |  

The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…